文章：

转移性胰腺癌的管理——近五年全球指南比较

Management of Metastatic Pancreatic Cancer—Comparison of Global Guidelines over the Last 5 Years

原文发布日期：2 September 2023

DOI: 10.3390/cancers15174400

类型: Article

开放获取: 是

英文摘要：

Pancreatic cancer (PC) is usually diagnosed at an advanced stage of its development, which results in lower overall survival (OS). Prognosis is also poor even with curative-intent surgery. Approximately 80% of patients with localized PDAC have micrometastases at the time of diagnosis, which leads to a worse prognosis than in other cancers. The objective of this study is to present the progress in the treatment of metastatic pancreatic cancer based on the recommendations of oncological scientific societies, such as ESMO, NCCN, ASCO, NICE and SEOM, over the last 5 years. Combined FOLFIRINOX therapy is mostly a recommended therapy among patients with good performance statuses, while gemcitabine is recommended for more fragile patients as a first-line treatment. The newest guidelines suggest that molecular profiling of the tumor should be the first step in determining the course of treatment. The use of modern molecular therapies in patients with specific gene mutations should extend the survival of patients with this disease.

摘要翻译： 

胰腺癌通常在疾病晚期才被诊断，导致总体生存率较低。即使进行根治性手术，其预后依然不佳。约80%的局限性胰腺导管腺癌患者在确诊时已存在微转移，这导致其预后较其他癌症更差。本研究旨在基于ESMO、NCCN、ASCO、NICE和SEOM等肿瘤学科学协会近五年的建议，阐述转移性胰腺癌治疗进展。对于体能状态良好的患者，FOLFIRINOX联合疗法是主要推荐方案；而体质较弱的患者则建议将吉西他滨作为一线治疗。最新指南指出，肿瘤分子谱分析应作为制定治疗方案的首要步骤。对具有特定基因突变的患者采用现代分子疗法，有望延长此类患者的生存期。

原文链接：

Management of Metastatic Pancreatic Cancer—Comparison of Global Guidelines over the Last 5 Years